Cargando…

Efficacy and Safety of Two Different Enoxaparin Doses for Thromboprophylaxis in Non-critically Ill Patients: A Randomized Controlled Trial

BACKGROUND: Recently, a few studies based on anti-factor Xa activity levels have propounded doubtful and sub-prophylactic levels by the usual dose of enoxaparin in surgical and critically ill patients. In this study, we assessed two doses of enoxaparin in adult non-critically ill patients. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alavi-Darazam, Ilad, Forouhar, Kimia, Moradi, Omid, Saffaei, Ali, Asadi, Sara, Sahraei, Zahra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Briefland 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024325/ https://www.ncbi.nlm.nih.gov/pubmed/36942062 http://dx.doi.org/10.5812/ijpr-126555

Ejemplares similares

Evaluation of vancomycin pharmacokinetics in patients with augmented renal clearances: A randomized clinical trial
por: Sahraei, Zahra, et al.
Publicado: (2022)

Standard- versus intermediate-dose enoxaparin for anti-factor Xa guided thromboprophylaxis in critically ill patients with COVID-19
por: Hamilton, David Oliver, et al.
Publicado: (2021)

A comparative study of varying doses of enoxaparin for thromboprophylaxis in critically ill patients: a double-blinded, randomised controlled trial
por: Robinson, Sian, et al.
Publicado: (2013)

Effectiveness, safety, and costs of thromboprophylaxis with enoxaparin or unfractionated heparin in inpatients with obesity
por: Amin, Alpesh, et al.
Publicado: (2023)

Antifactor Xa Levels in Critically Ill Korean Patients Receiving Enoxaparin for Thromboprophylaxis: A Prospective Observational Study
por: Lim, So Yeon, et al.
Publicado: (2013)

Enoxaparin 20 mg for thromboprophylaxis in severe renal impairment
por: Karaoui, Lamis R., et al.
Publicado: (2018)

Optimal Dosing of Enoxaparin in Critically Ill Patients with Venous Thromboembolism
por: Abdulla, Aliya, et al.
Publicado: (2023)

Dosing of thromboprophylaxis and mortality in critically ill COVID-19 patients
por: Jonmarker, Sandra, et al.
Publicado: (2020)

Outcomes of thromboprophylaxis with enoxaparin vs. unfractionated heparin in medical inpatients
por: McGarry, Lisa J, et al.
Publicado: (2006)

Comparison of the Efficacy and Safety of Rivaroxaban and Enoxaparin as Thromboprophylaxis Agents for Orthopedic Surgery—Systematic Review and Meta-Analysis
por: Rinaldi, Ikhwan, et al.
Publicado: (2022)

Anti-factor Xa Activity Is Not Associated With Venous Thromboembolism in Critically Ill Patients Receiving Enoxaparin for Thromboprophylaxis: A Retrospective Observational Study
por: Dibiasi, Christoph, et al.
Publicado: (2022)

Efficacy and safety of enoxaparin as deep vein thrombosis prophylaxis in critically ill patients
por: Al-Hubail, R, et al.
Publicado: (2012)

Adequate thromboprophylaxis in critically ill patients
por: Levi, Marcel
Publicado: (2010)

Comparison of efficiency and safety of rivaroxaban, apixaban and enoxaparin for thromboprophylaxis after arthroplastic surgery: a meta-analysis
por: Yu, Zhi, et al.
Publicado: (2018)

Prophylactic anticoagulation with low dose enoxaparin: is the subcutaneous route appropriate in the critically ill?
por: Priglinger, U, et al.
Publicado: (2002)

Evaluation of the prophylactic effect of hydroxychloroquine on people in close-contact with patients with COVID-19
por: Shabani, Minoosh, et al.
Publicado: (2021)

An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19: A structured summary of a study protocol for a randomized controlled l trial
por: Alavi Darazam, Ilad, et al.
Publicado: (2020)

Antipseudomonal β-Lactams Resistance in Iran
por: Rabiei, Mohammad Mahdi, et al.
Publicado: (2020)

Renal function and thromboprophylaxis in critically ill patients
por: Scholey, Gareth M, et al.
Publicado: (2010)

Resistance of Streptococcus Pneumoniae to Macrolides in Iran
por: Shokouhi, Shervin, et al.
Publicado: (2019)

Dexamethasone Induced Sino-Orbital Mucormycosis In a Patient Infected With COVID-19
por: Mardani, Masoud, et al.
Publicado: (2022)

Pharmacokinetics of enoxaparin in COVID-19 critically ill patients
por: Zufferey, Paul Jacques, et al.
Publicado: (2021)

Postoperative decreased levels of D-dimer in patients with gynecologic cancer with enoxaparin and fondaparinux thromboprophylaxis
por: KODAMA, JUNICHI, et al.
Publicado: (2013)

Thromboprophylaxis in Critically Ill Coronavirus Disease 2019 Patients
por: Piagnerelli, Michaël, et al.
Publicado: (2020)

Community-acquired methicillin-resistant Staphylococcus aureus carriage rate and antimicrobial susceptibility in a tertiary center, Iran
por: Shokouhi, Shervin, et al.
Publicado: (2017)

Accuracy of Low-Dose Chest CT Scan in Detection of COVID-19
por: Bahrami-Motlagh, Hooman, et al.
Publicado: (2020)

Type of anaesthesia and the safety and efficacy of thromboprophylaxis with enoxaparin or dabigatran etexilate in major orthopaedic surgery: pooled analysis of three randomized controlled trials
por: Rosencher, Nadia, et al.
Publicado: (2012)

Bemiparin versus enoxaparin as thromboprophylaxis following vaginal and abdominal deliveries: a prospective clinical trial
por: Alalaf, Shahla K, et al.
Publicado: (2015)

Case report: Successful thromboprophylaxis with enoxaparin in a pregnant woman with internal jugular vein agenesis
por: Di Micco, Pierpaolo, et al.
Publicado: (2022)

Anti-activated factor × response to enoxaparin in critically ill patients
por: Einav, S, et al.
Publicado: (2009)

A 35-Year-Old Man with Dyspnea and Hemoptysis
por: Darazam, Ilad Alavi, et al.
Publicado: (2012)

Human Respiratory Syncytial Virus and Coronavirus Rates in Iranian Elderly Patients More than 60 Years Old with Acute Respiratory Symptoms
por: Tavakolian, Shaian, et al.
Publicado: (2023)

Heparin thromboprophylaxis in critically ill patients: Is it really changing outcome?
por: Gurjar, Mohan
Publicado: (2014)

Enhanced thromboprophylaxis in critically ill patients with COVID-19 infection
por: Kummer, R.L., et al.
Publicado: (2021)

Intensified thromboprophylaxis in COVID-19 critically ill patients: Is it enough?
por: de Montmollin, Etienne, et al.
Publicado: (2021)

Thromboprophylaxis with argatroban in critically ill patients with sepsis: a review
por: Bachler, Mirjam, et al.
Publicado: (2022)

Effects of thromboprophylaxis on mesenchymal stromal cells during osteogenic differentiation: an in-vitro study comparing enoxaparin with rivaroxaban
por: Pilge, Hakan, et al.
Publicado: (2016)

Comparison of Postoperative Bleeding in Total Hip and Knee Arthroplasty Patients Receiving Rivaroxaban, Enoxaparin, or Aspirin for Thromboprophylaxis
por: Lindquist, Desirae E., et al.
Publicado: (2018)

Comparison of Anti-factor Xa Levels in Female and Male Patients with Obesity After Enoxaparin Application for Thromboprophylaxis
por: Wagner, Jonas, et al.
Publicado: (2022)

Thromboprophylaxis in critical care
por: Helms, Julie, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dsfubtbhiofdsu4t4dade8iakq